Hydrocodone apap5mg 500mg tabs
Based on Basic EPS At the Floor Price - [•]% and [•]% based on Standalone and Consolidated financial statements respectively. At the Cap Price - [•]% and [•]% based on Standalone and Consolidated financial statements respectively.
Based on Diluted EPS drug urinalysis cutoff information on hydrocodone level hydrocodone At the Floor Price - [•]% and [•]% based on Standalone and Consolidated financial statements respectively. At the Cap Price - [•]% and [•]% based on Standalone and Consolidated financial statements respectively.
Net Asset Value per Equity Share Period NAV (?) Consolidated Standalone Year ended March 31, 2010 107.9 123.5 Year ended March 31, 2011 89.4 90.hydrocodone apap5mg 500mg tabs 3 Year ended March 31, 2012 111.3 127.0 Period NAV (?) Consolidated Standalone Period ended December 31, 2012 NAV after the Issue Issue Price 146.0 190.3 [•] [•] Net worth excluding revaluation reserve and preference share Net Asset Value per Equity Share (?) = . , capital , • , r at the end of the year/ period Number of equity shares outstanding at the end of the year/period *The Issue Price of ' [•] per Equity Share has been determined on the basis of the demand from investors through the Book Building hydrocodone apap5mg 500mg tabs Process and is justified based hydrocodone apap5mg 500mg tabs on the above accounting ratios. Comparison with industry peers Consolidated/ Period Face Value For the period ended Standalone Ended per equity share (?) EPS O P/E# RoNW (%) NAV O Intas Pharmaceuticals Standalone December 2012 10 41.4 21.5 190.3 Intas Pharmaceuticals Consolidated December 2012 10 27.7 18.8 146.0 Sun Pharmaceutical Consolidated March 2013 1 29.0 34.9 23.3 145.0 Cadila Healthcare Consolidated March 2013 5 32.hydrocodone apap5mg 500mg tabs 0 24.1 22.8 148.5 CiplaA Consolidated March 2013 2 19.2 19.4 17.1 112.2 Glenmark PharmaceuticalsA Consolidated March 2013 1 22.7 25.4 22.5 102.0 Torrent Pharmaceuticals Consolidated March 2013 5 51.2 16.0 30.6 168.1 IPCA A Laboratories Consolidated March 2013 2 25.7 23.5 20.9 123.1 Source: Audited financials for nine months ended December 31, 2012 ^Audited financials for the year ended March 2013 from respective company websites # P/E calculated based on closing share price on June 7, 2013 from BSE Website (www.bseindia.com) The peer group listed companies as stated above are engaged in the pharmaceuticals business. The Issue Price of ' [•] has been determined by the Company, in consultation with the BRLMs on the basis of the demand from investors for the Equity Shares determined through the Book Building process and is justified based on the above accounting ratios. For further details, please see the section entitled "vicodin online pharmacy no prior prescription no memberships c.o.d Risk Factors" on page 14 and the financials of the Company including important profitability and hydrocodone/ guaifenesin syrup return ratios, as set out in the section entitled "Financial Statements" on page F-1. The Board of Directors Intas Pharmaceuticals somit zolpidem 10mg Limited 2nd floor, Chinubhai Centre, Ashram Road, Ahmedabad - 380 009 Gujarat, India Dear Sirs, Statement of Possible Tax Benefits available to Intas Pharmaceuticals Limited and its shareholders We hereby report that the enclosed statement states the possible tax benefits available to Intas Pharmaceuticals Limited ("the Company") under the Income Tax Act, 1961, presently in force in India and to the shareholders of the Company under the Income Tax Act, 1961 and other Direct Tax Laws presently in force in India.
Ambien generic link online tramadol
Straterra combined with adderall
Inc log 2 discount phentermine